AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Diseas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| AbbVie (NYSE: ABBV) | Delayed: 285.19 +0.39 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $284.80 | 52 Week High | $68.12 | |||
| Open | $284.57 | 52 Week Low | $50.71 | |||
| Day High | $285.76 | P/E | 61.86 | |||
| Day Low | $278.01 | EPS | $4.61 | |||
| Volume | 6,174,400 | |||||
